For Healthcare Professionals

A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)


About the study

The purpose of this study is to evaluate the efficacy and safety of telitacicept in the treatment of moderately to severely active SLE.

Who can take part

You may be eligible to participate in the study if you meet the following criteria:


Inclusion Criteria:

Has had a diagnosis of SLE for at least 6 months prior to the screening Visit.

Moderate to severely active SLE is defined by the following:

  1. Hybrid SELENA SLEDAI (hSLEDAI) total score ≥ 6 at screening with clinical hSLEDAI score ≥ 4 points
  2. BILAG-2004 organ system scores of at least 1 A or 2 B at screening.
  3. Clinical hSLEDAI score of ≥ 4 at Day 0 prior to randomization
  4. At least one positive serologic parameter within the screening period
  5. Currently receiving at least one of the SOC SLE medications: oral corticosteroid, antimalarial and/or immunosuppressive agent.
  6. Other protocol defined inclusion criteria may apply.


Exclusion Criteria:

  1. Active or unstable neuropsychiatric SLE or lupus nephritis
  2. Autoimmune or rheumatic disease other than SLE
  3. Significant, uncontrolled medical conditions not related to SLE
  4. Active and/or severe viral, bacterial or fungal infection
  5. History of malignancy within 5 years
  6. Other protocol defined exclusion criteria may apply.

pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.

Study’s details


Systemic Lupus Erythematosus

Age (in years)

12 - 70


Phase 3

Participants needed


Est. Completion Date

Sep 21, 2025

Treatment type



RemeGen Co., Ltd. identifier


Study number


Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.